Acutus Medical
(NASDAQ:AFIB)
$0.1691
-0.0013[-0.76%]
At close: Apr 15
$0.1691
0[0.00%]
PreMarket: 4:07PM EDT
Consensus Rating1
Underweight
Highest Price Target1
$3.00
Lowest Price Target1
$1.50
Consensus Price Target1
$1.50

Acutus Medical Stock (NASDAQ:AFIB), Analyst Ratings, Price Targets, Predictions

Acutus Medical Inc has a consensus price target of $1.5, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from Goldman Sachs, BTIG, and BTIG on August 16, 2022, June 24, 2022, and April 27, 2022. With an average price target of $1.67 between Goldman Sachs, BTIG, and BTIG, there's an implied 885.61% upside for Acutus Medical Inc from these 3 analyst ratings.

Analyst Rating
12345
3.1
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Goldman Sachs
BTIG
Canaccord Genuity
JP Morgan

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Acutus Medical

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
08/16/2022AFIBBuy Now
Acutus Medical
$0.17787.05%Goldman Sachs
Amit Hazan
$1 → $1.5MaintainsNeutralGet Alert
06/24/2022AFIBBuy Now
Acutus Medical
$0.17787.05%BTIG
Marie Thibault
$2 → $1.5MaintainsBuyGet Alert
04/27/2022AFIBBuy Now
Acutus Medical
$0.171082.73%BTIG
Marie Thibault
→ $2UpgradeNeutral → BuyGet Alert
04/14/2022AFIBBuy Now
Acutus Medical
$0.17491.37%Goldman Sachs
Amit Hazan
$5 → $1MaintainsNeutralGet Alert
01/20/2022AFIBBuy Now
Acutus Medical
$0.17BTIG
Marie Thibault
DowngradeBuy → NeutralGet Alert
01/14/2022AFIBBuy Now
Acutus Medical
$0.171674.1%Canaccord Genuity
William Plovanic
$10 → $3DowngradeBuy → HoldGet Alert
11/12/2021AFIBBuy Now
Acutus Medical
$0.17JP Morgan
Robbie Marcus
DowngradeNeutral → UnderweightGet Alert
11/12/2021AFIBBuy Now
Acutus Medical
$0.175813.66%Canaccord Genuity
William Plovanic
MaintainsBuyGet Alert
10/22/2021AFIBBuy Now
Acutus Medical
$0.175813.66%Goldman Sachs
Amit Hazan
Initiates → NeutralGet Alert
07/15/2021AFIBBuy Now
Acutus Medical
$0.1710544.59%Canaccord Genuity
William Plovanic
UpgradeHold → BuyGet Alert

FAQ

Q

What is the target price for Acutus Medical (AFIB)?

A

The latest price target for Acutus Medical (NASDAQ: AFIB) was reported by Goldman Sachs on August 16, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 787.05% upside). 0 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acutus Medical (AFIB)?

A

The latest analyst rating for Acutus Medical (NASDAQ: AFIB) was provided by Goldman Sachs, and Acutus Medical maintained their neutral rating.

Q

When was the last upgrade for Acutus Medical (AFIB)?

A

The last upgrade for Acutus Medical Inc happened on April 27, 2022 when BTIG raised their price target to $2. BTIG previously had a neutral for Acutus Medical Inc.

Q

When was the last downgrade for Acutus Medical (AFIB)?

A

The last downgrade for Acutus Medical Inc happened on January 20, 2022 when BTIG changed their price target from N/A to N/A for Acutus Medical Inc.

Q

When is the next analyst rating going to be posted or updated for Acutus Medical (AFIB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.

Q

Is the Analyst Rating Acutus Medical (AFIB) correct?

A

While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $0.17, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch